RxDoctor Payments Data

Steven Wittmer, MD

Internal Medicine · Fairhope, ALNPI 1104820869

Payments from drug & device makers

$8,645in general payments, 2019–2025

Across 595 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$917
  • Lilly USA, LLC$690
  • Pfizer$685
  • AstraZeneca$507
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$490
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,56599%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,645 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$69,891
Medicare patients
134
Services billed
1,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$61,353
EliquisApixaban53$54,746
MounjaroTirzepatide37$36,753
FarxigaDapagliflozin Propanediol26$30,693
OxycontinOxycodone Hcl12$24,648
LinzessLinaclotide25$24,387
JardianceEmpagliflozin16$21,550
TrulicityDulaglutide21$20,044
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$15,930
MyrbetriqMirabegron12$13,709
XareltoRivaroxaban14$13,394
TrintellixVortioxetine Hydrobromide16$12,029
Oxycodone Hcl93$7,110
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen106$3,459
Gabapentin176$3,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,240$61,35348 claims
Lilly USA, LLCMounjaro, Trulicity$690$56,79758 claims
PfizerEliquis, Paxlovid$685$56,17572 claims
AstraZenecaFarxiga$507$30,69326 claims
AbbVieLinzess, Synthroid$917$27,29547 claims
Boehringer IngelheimJardiance$65$21,55016 claims
GSKTrelegy Ellipta$365$15,93012 claims
Astellas Pharma US IncMyrbetriq$256$13,70912 claims
Johnson & JohnsonXarelto$320$13,39414 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$144$12,02916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →